Arca
Skip to content
Tools
Tools

CD38: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands.

  • Drugs that act on it: 5
  • Approved: 2
  • In phases 1 to 3: 3
  • Sponsors: 4

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CD38, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody
  • Other

Approved2

  • Daratumumab
  • Isatuximab

Phase 31

  • Felzartamab

Phase 22

  • Mezagitamab
  • HUMAX-IL15

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Antibody480%
    • Other120%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 4 of 5 act as: Lymphocyte differentiation antigen CD38 inhibitor; the rest name their own mechanism.
    DaratumumabApprovedJohnson & JohnsonAntibodyInhibitor—233—
    IsatuximabApprovedSanofiAntibodyInhibitor—71—
    FelzartamabPhase 3BiogenAntibodyInhibitor—8—
    MezagitamabPhase 2Takeda Pharmaceuticals USAAntibodyBinding agentLymphocyte differentiation antigen CD38 binding agent4—
    HUMAX-IL15Phase 2—OtherInhibitor—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 28 in all, from ClinicalTrials.gov.
    A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years OldFelzartamabPhase 2Not yet recruitingBiogen2026-11-16
    A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131DaratumumabPhase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.2026-11-12
    BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple MyelomaDaratumumabPhase 1Not yet recruitingLiping Dou2026-11-10
    QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II StudyIsatuximabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-11-06
    Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaDaratumumabPhase 3Not yet recruitingKeymed Biosciences Co.Ltd2026-11-02
    Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical TrialDaratumumabPhase 2Active, not recruitingFirst Affiliated Hospital, Sun Yat-Sen University2026-10-29
    A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligibleDaratumumabPhase 3Not yet recruitingJanssen Research & Development, LLC2026-10-29
    To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaIsatuximabPhase 3Not yet recruitingKite, A Gilead Company2026-10-29
    QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell LeukemiaIsatuximabPhase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China2026-10-29
    Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisDaratumumabPhase 3Not yet recruitingRegeneron Pharmaceuticals2026-10-28
    Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaDaratumumabPhase 2RecruitingTata Memorial Centre2026-10-23
    Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaDaratumumabPhase 2 / Phase 3Not yet recruitingAlliance for Clinical Trials in Oncology2026-10-22
    A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)FelzartamabPhase 2Not yet recruitingBiogen2026-10-22
    F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple MyelomaIsatuximabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-09-18
    Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple MyelomaIsatuximabPhase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China2026-08-27
    Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTIsatuximabPhase 3RecruitingAstraZeneca2026-08-14
    Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma CellsIsatuximabPhase 2 / Phase 3Not yet recruitingThe Affiliated People's Hospital of Ningbo University2026-07-29
    A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years OldFelzartamabPhase 2RecruitingBiogen2026-07-23
    Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic AnemiaIsatuximabPhase 1 / Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China2026-07-20
    A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney TransplantMezagitamabPhase 2RecruitingTakeda2026-05-29
    A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)FelzartamabPhase 3Enrolling by invitationBiogen2026-03-03
    A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular InflammationFelzartamabPhase 2RecruitingBiogen2025-10-21
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyMezagitamabPhase 3RecruitingTakeda2025-05-09
    A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)FelzartamabPhase 3RecruitingBiogen2025-05-08
    A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaMezagitamabPhase 3RecruitingTakeda2025-04-29
    A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)FelzartamabPhase 3RecruitingBiogen2025-04-20
    A Study of Mezagitamab in Adults With Chronic Primary Immune ThrombocytopeniaMezagitamabPhase 3RecruitingTakeda2024-12-09
    A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)FelzartamabPhase 3Active, not recruitingBiogen2024-11-12

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Plasma cell myeloma
    0.63
    Neoplasm
    0.49
    Parkinson disease
    0.47
    Smoldering plasma cell myeloma
    0.36
    Autoimmune thrombocytopenic purpura
    0.35
    AL amyloidosis
    0.32
    Self-injurious ideation
    0.29
    Acute leukemia
    0.27
    Autoimmune encephalitis
    0.26

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4660, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P28907, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.